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How High Is the Price of Anticoagulation?*Richard W. Asinger, MD, Gautam R. Shroff, MBBSF or over a half century, vitamin K antagonists,chieﬂy warfarin, were the exclusive oral anti-coagulants available for long-term anticoagu-
lation. Being “the only game in town,” the emphasis
of the accompanying clinical research was focused
on determining the most appropriate method to mea-
sure anticoagulant effects, deﬁne the most efﬁcacious
and safe target range for anticoagulation, and identify
strategies to maintain and reverse therapeutic anti-
coagulation. This emphasis came at the expense of
turning a blind eye to rare concerns raised about
the potential for warfarin to cause or worsen renal
dysfunction (1,2). The approval of dabigatran for pre-
vention of stroke and systemic embolism in patients
with nonvalvular atrial ﬁbrillation (NVAF) ushered in
a new era in long-term oral anticoagulation (3). Prog-
ress in this era has been unprecedented in recent
years, and there are now several newer oral anticoagu-
lant (NOAC) options approved by the U.S. Food and
Drug Administration for clinical use (4). Interestingly,
clinicians now ﬁnd themselves in the relatively un-
comfortable position of having to choose the “best”
option among anticoagulants for their patients. The se-
lection of the most appropriate oral anticoagulant can
be a complex, multistep process that is based on the
consideration of several clinical variables including,
importantly, the assessment of renal function (4).SEE PAGE 2481In this issue of the Journal, the study by Böhm
et al. (5) is, therefore, timely and renews previously
raised concerns about the detrimental effects of
vitamin K antagonists on renal function. In this*Editorials published in the Journal of the American College of Cardiology
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thors longitudinally assessed estimated glomerular
ﬁltration rate (eGFR) among 16,490 patients assigned
to therapy with dabigatran 110 mg twice daily, dabi-
gatran 150 mg twice daily, or adjusted-dose warfarin.
Although the reduction in eGFR was numerically
higher among the dabigatran arms in the short term,
after an average follow-up of 30 months, there was a
modest but statistically signiﬁcant reduction in eGFR
in the warfarin group compared with the dabigatran
arms. The authors appropriately acknowledge that
the decline in eGFR with warfarin in comparison with
dabigatran was small despite the long follow-up
period in this large trial. Additional sensitivity
analysis, based on time to deterioration of eGFR
>25% (especially during the later phases of the trial),
also supported the primary analysis. This study has
several strengths including robust, albeit complex
and exhaustive, statistical analyses, a thoughtful and
deliberate choice of tools (Chronic Kidney Disease
Epidemiology Collaboration equation for eGFR esti-
mation), and clinical parameters (25% reduction in
eGFR) that are meaningful to the clinician.
Importantly, the ﬁndings reported are directionally
concordant with previous reports of nephropathy
described among patients receiving warfarin therapy,
hypothesized to occur from the effects of inhibition of
the vitamin K–dependent protein gamma carbox-
yglutamic acid (Gla/MGP) and/or a speciﬁc nephrop-
athy from episodic glomerular hemorrhage (1,2). The
observations pertaining to greater reductions in eGFR
among patients with previous warfarin use and supra-
therapeutic international normalized ratio values
could suggest a “dose” effect, lending credence to the
latter theory. It is, therefore worth noting that the
decline in eGFR in this study was similar in both
dabigatran arms, even though the overall incidence of
major hemorrhage in RE-LY was higher in the dabiga-
tran 150 mg twice-daily arm (3). If glomerular hemor-
rhage was indeed the sole mechanism responsible for
decline in eGFR with oral anticoagulation, one might
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2495have expected a similar trend with the higher dabiga-
tran dose, but this was not observed. Thus, an alter-
native mechanism responsible for the reduction in
eGFR in the warfarin group, such as renal vascular
calciﬁcation (2), might be hypothesized as the pre-
dominant mechanism, although this is purely specu-
lative. Owing to the retrospective nature of the
analysis, it is not feasible to account for all relevant
clinical variables, such as concomitant medications or
procedural interventions (such as coronary angiog-
raphy) that may contribute to renal dysfunction.
Overall, the authors are to be congratulated for the
innovative use of data from a large, randomized trial
on long-term oral anticoagulation to address a theo-
retical and occasionally raised question with im-
portant clinical implications. Although it would be
desirable to conﬁrm these ﬁndings in a prospective
fashion, the extraordinarily large number of patients
from the RE-LY trial needed to demonstrate these
ﬁndings highlight the fact that any absolute reduction
in eGFR with warfarin is really quite modest compared
with both doses of dabigatran. Thus, even though
these observations probably are not a “game changer”
for clinicians, ﬁne-tuning of clinical practice would be
appropriate with attention to these ﬁndings.
From a somewhat broader perspective, this study
brings into light the observation of a continuous
decline in eGFR among all three arms in this elderly
cohort of patients with NVAF receiving therapeutic
anticoagulation. Although this message is not neces-
sarily novel, it is extremely pertinent in the context of
escalating use of NOACs worldwide and implications
for dose adjustments to avoid drug accumulation
and excessive hemorrhage. In the absence of a pla-
cebo arm, it is not possible to determine if a de-
cline in eGFR occurs among all patients with NVAF,
simply among patients receiving therapeutic anti-
coagulation, or only among patients being anti-
coagulated with speciﬁc agents. Although the clinical
signiﬁcance of this reduction in eGFR (approximately
1 ml/min per year) can be debated, the overall mes-
sage is compelling and deserving of careful thought.
Deterioration of renal function among patients on
warfarin does not have direct implications for doseadjustments, but it certainly would have implications
for patients beginning therapy with or transitioning
therapy to NOACs, with important attendant impli-
cations for bleeding risk from accumulating levels of
these agents in the case of deteriorating eGFR.
In summary, for many decades, the medical com-
munity chose to ignore some of the pathophysiolog-
ical concerns pertaining to the effect of warfarin on
renal vascularity and function because warfarin was
the only viable option. By virtue of the availability of
several options for therapeutic anticoagulation now,
we can ﬁnally permit ourselves to take those self-
imposed blinders off and take a more critical look at
the clinical effects of these drugs. The study by Böhm
et al. (5) raises provocative questions about the ef-
fects of pharmacotherapy for atrial ﬁbrillation on
renal function but also serves to reassure that the
observed decline in eGFR with warfarin does not
appear to be a very heavy price to pay for its proven
beneﬁts. Other oral anticoagulant agents also should
be evaluated for any association with a similar phe-
nomenon of eGFR reduction because the results could
inﬂuence dosing. For now, warfarin will continue to
have an important role in contemporary therapeutic
anticoagulation for NVAF for the simple reason that its
anticoagulant effect can be easily measured clinically,
and this may be especially desirable for select patient
populations, including, ironically, patients with ﬂuc-
tuating renal dysfunction. We hope that studies like
this provide an impetus to the cardiology/nephrology
and pharmaceutical communities to design compara-
tive effectiveness studies among the NOAC agents,
particularly among select subsets such as patients
with chronic kidney disease and diabetes. On the basis
of the burgeoning epidemiology and clinical impor-
tance of renal dysfunction among patients with NVAF,
it is clear that longitudinal assessment of eGFR would
be an important endpoint in such studies.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Richard W. Asinger, Hennepin County Medical Cen-
ter, Division of Cardiology, 701 Park Avenue South,
Orange 5, Minneapolis, Minnesota 55415. E-mail:
asing001@umn.edu.RE F E RENCE S1. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-
related nephropathy occurs in patients with and
without chronic kidney disease and is associated with
anincreasedmortality rate.KidneyInt2011;80:181–9.
2. Chatrou ML, Winckers K, Hackeng TM, et al.
Vascular calciﬁcation: the price to pay for anti-
coagulation therapy with vitamin K-antagonists.
Blood Rev 2012;26:155–66.3. Connolly SJ, Ezekowitz MD, Yusuf S, et al.
Dabigatran versus warfarin in patients with
atrial ﬁbrillation. N Engl J Med 2009;361:
1139–51.
4. Kovacs RJ, Flaker GC, Saxonhouse SJ, et al.
Practical management of anticoagulation in pa-
tients with atrial ﬁbrillation. J Am Coll Cardiol
2015;65:1340–60.5. Böhm M, Ezekowitz MD, Connolly SJ, et al.
Changes in renal function in patients with atrial
ﬁbrillation: an analysis from the RE-LY trial. J Am
Coll Cardiol 2015;65:2481–93.KEY WORDS anticoagulation, atrial ﬁbrillation,
dabigatran, warfarin, warfarin nephropathy
